<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>POSSIBILITIES OF MODERN THERAPY OF LIVER CIRRHOSIS AND TYPE 2 HEPATORENAL SYNDROME</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Jumayeva M.F.</mods:namePart><mods:namePart type="family">Jumayeva M.F.</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Ahmedova N.Sh.</mods:namePart><mods:namePart type="family">Ahmedova N.Sh.</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Hepatorenal syndrome (HRS) is a severe complication that occurs in patients with cirrhosis of the liver (LC), characterized by clinical manifestations of renal failure (RF). Type 2 HRS is observed in patients with severe ascites that are refractory to diuretics. The average survival time of patients with type 2 HRS is 6 months. The laboratory criteria for type 2 HRS are the level of creatinine in the blood serum (above 150 mmol/l), characterized by a high plasma content of renin, aldosterone and antidiuretic hormone. Kidney failure develops slowly .</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-01-22</mods:dateIssued></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>